urispas 200 tablets
dowelhurst ltd - flavoxate hydrochloride - oral tablet - 200mg
urispas 200 tablets
stephar (u.k.) ltd - flavoxate hydrochloride - oral tablet - 200mg
urispas 200 tablets
mawdsley-brooks & company ltd - flavoxate hydrochloride - oral tablet - 200mg
urorec capsules hard
recordati industria chimica e farmaceutica s.p.a. - silodosin - capsules hard - 8mg
urorec capsules hard
recordati industria chimica e farmaceutica s.p.a. - silodosin - capsules hard - 4mg
urorec capsules hard
recordati industria chimica e farmaceutica s.p.a. - silodosin - capsules hard - 8mg
qarziba dinutuximab beta 4.5 mg/ml concentrate for solution for infusion, 20 mg/4.5 ml vial
recordati rare diseases australia pty ltd - dinutuximab beta, quantity: 4.5 mg/ml - solution - excipient ingredients: polysorbate 20; hydrochloric acid; sucrose; water for injections; histidine - qarziba is indicated for the treatment of high-risk neuroblastoma in patients who have previously received induction chemotherapy and achieved at least a partial response.
zanidip 20mg, film-coated tablet
abbott laboratories (m) sdn. bhd. - lercanidipine -
livazo tablets film-coated
recordati industria chimica e farmaceutica s.p.a. - pitavastatin (pitavastatin calcium) - tablets film-coated - 1mg
signifor- pasireotide injection
recordati rare diseases, inc. - pasireotide (unii: 98h1t17066) (pasireotide - unii:98h1t17066) - signifor is indicated for the treatment of adult patients with cushing's disease for whom pituitary surgery is not an option or has not been curative. none. risk summary the limited data with signifor in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage. in embryo-fetal development studies in rabbits, findings indicating developmental delay were observed with subcutaneous administration of pasireotide during organogenesis at doses less than the exposure in humans at the highest recommended dose; maternal toxicity was not observed at this dose (see data) . the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively. data animal data in embryo-fetal development studies in rats given 1, 5, and 10 mg/kg/day subcutaneously throughout org